Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

DOI PDF 被引用文献6件 参考文献20件
  • Elena Santagostino
    Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy;
  • Uri Martinowitz
    The Israeli National Haemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel;
  • Toshko Lissitchkov
    Department of Coagulation Disorders and Anemia, Specialized Hospital for Active Treatment Joan Pavel, Sofia, Bulgaria;
  • Brigitte Pan-Petesch
    Centre Hospitalier Régional Universitaire de Brest, Hôpital A. Morvan, Brest, France;
  • Hideji Hanabusa
    Department of Hematology, Ogikubo Hospital, Tokyo, Japan;
  • Johannes Oldenburg
    Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany;
  • Lisa Boggio
    Rush Hemophilia and Thrombophilia Center, Rush University, Chicago, IL;
  • Claude Negrier
    Centre Régional de Traitement de l’Hémophilie, Hôpital Edouard Herriot, University Claude Bernard, Lyon, France;
  • Ingrid Pabinger
    Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria;
  • Mario von Depka Prondzinski
    Werlhof Institut, Hannover, Germany;
  • Carmen Altisent
    Unitat Hemofilia, Hospital Vall d’Hebron, Barcelona, Spain;
  • Giancarlo Castaman
    Haemophilia and Thrombosis Centre, Department of Haematology, San Bortolo Hospital, Vicenza, Italy;
  • Koji Yamamoto
    Nagoya University Hospital, Nagoya, Japan;
  • Maria-Teresa Álvarez-Roman
    Hospital la Paz, Madrid, Spain; and
  • Christine Voigt
    Clinical Research and Development, CSL Behring, King of Prussia, PA
  • Nicole Blackman
    Clinical Research and Development, CSL Behring, King of Prussia, PA
  • Iris Jacobs
    Clinical Research and Development, CSL Behring, King of Prussia, PA

説明

<jats:title>Key Points</jats:title> <jats:p>rIX-FP maintains mean trough of 20 and 12 IU/dL FIX activity with 40 IU/kg weekly and 75 IU/kg every 2 weeks prophylaxis, respectively. Weekly and 14-day prophylaxis regimens with rIX-FP were well tolerated and provided low bleeding rates and target joint improvement.</jats:p>

収録刊行物

  • Blood

    Blood 127 (14), 1761-1769, 2016-04-07

    American Society of Hematology

被引用文献 (6)*注記

もっと見る

参考文献 (20)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ